Thursday, April 28, 2016

Profound Medical sells first TULSA-PRO device

Profound Medical sells first TULSA-PRO device

April 28, 2016 by · Leave a Comment 

Tweet Profound Medical (TSX-V:PRN) has made the first sale of its TULSA-PRO device to ResoFus Alomar in Barcelona, Spain. Profound’s novel technology combines real-time magnetic resonance imaging with transurethral robotically driven ultrasound and closed-loop thermal feedback control, providing a highly precise treatment tailored to patient-specific anatomy and pathology. TULSA-PRO has demonstrated accurate and precise ablation […]

Transition Therapeutics begins Phase 2 SARM study

Transition Therapeutics begins Phase 2 SARM study

April 26, 2016 by · Leave a Comment 

Tweet Transition Therapeutics (NASDAQ:TTHI, TSX:TTH) has dosed the first patient in a Phase 2 study of selective androgen receptor modulator (SARM) drug candidate, TT701. The Phase 2 study will evaluate the efficacy and safety of TT701 in improving the symptoms of androgen deficiency, including sexual symptoms, fatigue/low vitality, and physical dysfunction in men who have […]

GMP starts Profound Medical at speculative buy

GMP starts Profound Medical at speculative buy

April 12, 2016 by · Leave a Comment 

Tweet GMP Securities has initiated coverage of Profound Medical (TSX-V:PRN) with a “speculative buy” rating and price target of $2. The stock closed at $1.50 on Monday. The company is focused on developing and commercializing an innovative therapy for the ablation of prostate cancer tissue, using real-time MRI to greatly improve accuracy, while reducing side […]

Soricimed to present four posters at AACR

Soricimed to present four posters at AACR

April 12, 2016 by · Leave a Comment 

Tweet Closely-held Soricimed Biopharma and collaborators plan to present four posters at the American Association of Cancer Research (AACR) annual meeting in New Orleans on April 16-20. The presentations are based on preclinical and clinical research conducted on the company’s lead anti-cancer drug candidate, SOR-C13, a first-in-class inhibitor of the TRPV6 calcium channel. In February, […]

Profound Medical receives CE Mark to sell Tulsa-Pro

Profound Medical receives CE Mark to sell Tulsa-Pro

April 11, 2016 by · Leave a Comment 

Tweet Profound Medical (TSX-V:PRN) has received CE Mark approval for the commercial sale of Tulsa-Pro. Profound’s novel technology combines real-time magnetic resonance imaging with transurethral robotically-driven ultrasound and closed-loop thermal feedback control to provide a highly precise treatment tailored to patient-specific anatomy and pathology. TULSA-PRO has demonstrated accurate and precise ablation of prostate tissue, both […]

FDA clears BriaCell for BriaVax trial

FDA clears BriaCell for BriaVax trial

November 4, 2015 by · Leave a Comment 

Tweet The FDA has given final clearance for BriaCell Therapeutics’ (OTCQB:BCTXF; TSX-V:BCT) IND to initiate a Phase 1/2a clinical trial of its BriaVax vaccine. The open-label, non-randomized trial will enroll up to 24 breast cancer patients with advanced stages of disease. The clinical trial protocol has a provision to allow testing of the vaccine in […]

Transition Therapeutics sets Phase 2 SARM trial

Transition Therapeutics sets Phase 2 SARM trial

October 30, 2015 by · Leave a Comment 

Tweet Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has entered an agreement for an investigator-led clinical study of drug candidate, TT701, with Brigham and Women’s Hospital (BWH). Transition will support the Phase 2 study to evaluate selective androgen receptor modulator (SARM) drug candidate TT701 as a therapy to improve the symptoms of androgen deficiency in men with prostate cancer who […]

Can-Fite preparing protocol for advanced psoriasis trial

Can-Fite preparing protocol for advanced psoriasis trial

September 8, 2015 by · Leave a Comment 

Tweet Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) is preparing the protocol for its next advanced psoriasis trial with its CF101 oral drug candidate, even though an earlier Phase 2/3 study did not meet its primary endpoint. The earlier trial was designed to show a statistically significant improvement in the Psoriasis Area Severity Index (PASI) 75 score, […]

Knight to commercialize Advaxis drugs in Canada

Knight to commercialize Advaxis drugs in Canada

August 26, 2015 by · Leave a Comment 

Tweet Advaxis (NASDAQ:ADXS) has entered into a licensing agreement with Knight Therapeutics (TSX:GUD) to commercialize in Canada Advaxis’ product portfolio, including its three lead drug candidates: axalimogene filolisbac (ADXS-HPV) for human papilloma virus-associated cancers, ADXS-PSA for prostate cancer and ADXS-HER2 for HER2 expressing solid tumors. In connection with the licensing agreement, Knight is purchasing directly […]

HCW starts Biocept at buy

HCW starts Biocept at buy

August 19, 2015 by · Leave a Comment 

Tweet H.C. Wainwright has initiated coverage of Biocept (NASDAQ:BIOC) with a “buy” rating and $4 price target. The stock closed at $1.96 on Tuesday. Biocept is a commercial-stage company in the emerging field of liquid biopsy, focusing on the capture, enumeration and analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) from a blood […]

Next Page »

Email Newsletters with Constant Contact
Google+